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Abstract
Background: Delirium is common, affecting at least 20% of older hospital inpatients. It is widely accepted that
delirium is associated with dementia but the degree of causation within this relationship is unclear. Previous studies
have been limited by incomplete ascertainment of baseline cognition or a lack of prospective delirium assessments.
There is an urgent need for an improved understanding of the relationship between delirium and dementia given
that delirium prevention may plausibly impact upon dementia prevention. A well-designed, observational study
could also answer fundamental questions of major importance to patients and their families regarding outcomes
after delirium.
The Delirium and Cognitive Impact in Dementia (DECIDE) study aims to explore the association between delirium
and cognitive function over time in older participants. In an existing population based cohort aged 65 years and
older, the effect on cognition of an episode of delirium will be measured, independent of baseline cognition and
illness severity. The predictive value of clinical parameters including delirium severity, baseline cognition and
delirium subtype on cognitive outcomes following an episode of delirium will also be explored.
Methods: Over a 12 month period, surviving participants from the Cognitive Function and Ageing Study II-
Newcastle will be screened for delirium on admission to hospital. At the point of presentation, baseline
characteristics along with a number of disease relevant clinical parameters will be recorded. The progression/
resolution of delirium will be monitored. In those with and without delirium, cognitive decline and dementia will
be assessed at one year follow-up. We will evaluate the effect of delirium on cognitive function over time along
with the predictive value of clinical parameters.
Discussion: This study will be the first to prospectively elucidate the size of the effect of delirium upon cognitive
decline and incident dementia. The results will be used to inform future dementia prevention trials that focus on
delirium intervention.
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Background
Delirium is a severe neuropsychiatric syndrome of brain
dysfunction precipitated by acute illness. It is charac-
terised by acute and fluctuating inattention and other
cognitive and perceptual deficits.
Delirium is common, affecting at least 20% of older
hospital inpatients [1]. Delirium is particularly common
in older people and those with cognitive impairment.
The occurrence rate of delirium in general medical and
geriatric medicine wards was calculated at 29–64% [2].
However, delirium can occur in people of any age if the
physiological insult is great enough and affects up to
80% of those in intensive care [3].
Delirium is highly unpleasant and frightening for pa-
tients and their families, causing considerable short and
long-term distress [4]. People who have delirium during
their hospitalisation have increased lengths of stay [5],
more hospital-acquired complications, such as falls and
pressure sores, are more likely to need to be admitted to
long-term care following discharge from hospital and
are more likely to die [6]. These complications lead to
additional healthcare costs, estimated at an extra
£13,000 per admission [7].
Emerging literature indicates that delirium is a strong
predictor of new-onset dementia as well as acceleration
of existing cognitive decline [8–11]. This is consistent
across different settings: after hospitalisation [6]; in those
with dementia [8, 12]; in post-operative patients [13, 14];
after critical care [11]; and in community populations
[10, 15]. The only population-based study showed an 8
fold increased risk of cognitive decline following an epi-
sode of delirium [10]. Acute hospitalisation itself has
been shown to adversely affect trajectories of cognitive
decline, even when delirium has not been specifically
ascertained [16–18]. This implies that delirium and/or
its acute causes can contribute to the overall burden of
dementia.
Delirium was previously thought to be a benign and tran-
sient condition and, consequently, is under-researched, well
out of proportion to its prevalence and impact. The few
studies that do exist have several key limitations.
In existing delirium research, good quality, large epi-
demiological studies in unselected populations are lack-
ing which introduces selection bias and limits the
generalisability of results [19]. Dementia is a major risk
factor for delirium but many delirium studies list de-
mentia as an exclusion criterion, potentially resulting in
an underestimation of the true incidence of delirium.
It is likely that previous studies may have been con-
founded by incomplete ascertainment of cognitive status
at baseline [10], particularly given that around half of de-
mentia is undiagnosed [20]. Only one study of cognitive
trajectories in delirium has included baseline cognitive
assessments [10]. The major limitation of this work was
that delirium could not be prospectively defined. There
is a clear case for using prospective delirium assessments
particularly in the context of a cohort study as this
would allow for detailed assessment of the features of
delirium including severity, duration, and aetiology. It is
likely that such variations influence the risk of long-term
cognitive impairment [21].
Given the above, there is a need for population-based
studies to avoid the selection biases associated with much
of the current literature based solely on hospitalised sam-
ples [19, 21]. A study that prospectively tracks cognitive
change before, during and after delirium would address
many of the clinically important questions, including:
 To what extent does delirium influence cognitive
outcomes, over and above acute illness and
progressing frailty?
 What are the clinical features of delirium that have
the greatest impact on cognitive outcomes?
 Are there critical periods where delirium is more
harmful?
In a population based cohort study of men and women
aged 65 years and older, this study will measure the effect
on cognition of an episode of delirium, independent of
baseline cognitive status and illness severity. The study
will also explore the predictive value of clinical parameters
including delirium severity, baseline cognition, and delir-
ium subtype on cognitive outcomes following an episode
of delirium.
If this study shows that the relationship between delir-
ium and dementia is highly likely to be independently
contributory, it is reasonable to hypothesise that delir-
ium is a potentially modifiable risk factor for dementia.
This paves the way for future dementia prevention trials
that focus on delirium intervention.
Methods
Design
The Delirium and Cognitive Impact in Dementia (DE-
CIDE) study is a nested prospective longitudinal cohort
study. The study design, protocol and paperwork have
been reviewed and given favourable opinion by the New-
castle and North Tyneside 2 Regional Ethics Committee
(REC reference: 15/NE/0353).
Population
The study is embedded within the Cognitive Function
and Ageing Study II-Newcastle centre (CFAS II-
Newcastle). This is a large population based cohort of
individuals aged ≥65 years at baseline.
At baseline (2008–2011), 2500 participants were re-
cruited using primary care registration, which included
care settings, to CFAS II-Newcastle. Participants were
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re-seen two years later. Global as well as domain specific
cognitive function was assessed at baseline and two years
follow-up using the Geriatric Mental State (GMS), the
Cambridge Cognitive Examination (CAMCOG) and the
Mini Mental State Examination (MMSE). All partici-
pants sampled in CFAS II-Newcastle live within the
catchment area of the Newcastle-upon-Tyne Hospitals
NHS Foundation Trust. All surviving CFAS II-Newcastle
participants will be eligible to participate.
Recruitment
At the start of the DECIDE study, an introductory letter
and participant information sheet will be sent to all sur-
viving members of CFAS II-Newcastle by the CFAS team
detailing the proposed study. They will be invited to
contact the CFAS team if they do not want their NHS
number to be shared with the DECIDE study team.
During a one-year period, members of CFAS II-
Newcastle will be approached on emergency or elective
admission to hospital. In order to identify participants
admitted to hospital, an alert will be set up on the New-
castle upon Tyne hospitals electronic records system.
This will flag up participants on admission to the two
acute hospitals in Newcastle upon Tyne (Royal Victoria
Infirmary and Freeman Hospital). They will be
approached as soon as possible following admission.
Inclusion criteria
Any participant in CFAS II-Newcastle admitted to hos-
pital during the recruitment period will be invited to
take part. If the participant themselves lacks capacity, ac-
cording to a capacity assessment performed by the lead
researcher (SR), an appropriate personal consultee must
be available and provide written confirmation of willing-
ness to participate.
Exclusion criteria
Patients will be excluded from the study if they lack
capacity to consent and the study team are unable to
identify or contact an appropriate personal consultee.
Participants will also be excluded if they are receiving
end of life care. If the patient is being isolated for in-
fection control reasons, invitation to participate will
be delayed until they are no longer being isolated.
Participants in hospital for less than 24 hours will not
be included.
Data collection
The primary exposure is delirium during hospital admis-
sion, ascertained prospectively using a standardised pro-
cedure based on DSM-5 criteria [22] (Table 1). This
assessment combines objective testing of the participant,
lasting approximately ten minutes, with information
gained from informants (usually nurses, next of kin and
clinical records) and assessor’s judgement regarding sub-
jective features. Along with determining whether delir-
ium is present according to DSM-5, the assessment
enables scores to be generated for delirium severity,
based upon the Memorial Delirium Assessment Scale
[23], and motor subtype, based upon the Delirium
Motor Subtype Scale [24].
Participants will be assessed daily for the first five days
by SR or a clinical research nurse, both trained in the as-
sessment of delirium. From day 6, those with delirium
will continue to be seen daily until delirium resolution.
In the absence of delirium from day 6, or following reso-
lution of delirium, participants will be screened regularly
for delirium using a semi-structured interview including
a modified version of the Delirium Observation and
Screening Scale [25]. Should participants display any
signs of delirium according to this, the full assessment
described above will be performed to determine whether
DSM-5 delirium is present.
These assessments will enable the recording of the dur-
ation and characteristics of delirium or the development
of new delirium. It will be possible to follow the natural
history of the delirium in terms of any fluctuations, poten-
tial resolution and therefore estimate duration. The subse-
quent development of delirium in previously non-
delirious participants will also be captured. If it is not pos-
sible to review participants prospectively at any particular
time point, due to illness, refusal or study capacity, a vali-
dated tool will be used to retrospectively review the med-
ical records for a diagnosis of delirium [26].
Recruitment of hospital attendees will stop after
12 months. At this point, vignettes will be generated for
each participant and these will be sent to an expert con-
sensus panel (LA, SP, and DD). The panel will be tasked
with determining whether delirium was present, its sever-
ity, duration and subtype. The use of a consensus panel
enables an objective approach to determining these fac-
tors. Participants will be identified only by their unique
study identifier and will therefore be anonymised.
Participants will be invited to the study on every ad-
mission during the one year study period.
Illness severity will also be recorded during admission
using recognised illness severity measures (APACHE II
[27]/SOFA [28]/SAPS II [29]). There are a lack of vali-
dated tools to measure illness severity in older people.
Therefore, the utility of the HABAM [30] as a surrogate
marker for illness severity and recovery along with delir-
ium development/resolution will also be explored.
At random time-points throughout the study, joint as-
sessments of a sample of participants will be completed
to monitor inter-rater reliability and to optimise
consistency between assessors.
The advantage of using CFAS participants is that the
study population are well characterised at baseline.
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However, participants were last seen several years ago.
Therefore, to obtain an up to date estimate of baseline
functioning prior to admission, data will be collected on
each admission regarding independence (based on Barthel
Index of Activities of Daily Living), frailty (Rockwood
Clinical Frailty Score [31]), co-morbidities (CIRS-G [32]),
nutritional status (Malnutrition Universal Screening Tool
and BMI), polypharmacy (number of medications) and
anti-cholinergic burden (based on the ACB scale [33]).
The predictive value of these parameters will be explored.
During admission, possible causes of delirium will also be
recorded along with relevant delirium risk factors such as
ward moves, dehydration, constipation, pain and presence
or absence of sensory aids.
Outcomes
The primary outcome will be cognitive decline and/or de-
mentia 12 months after hospital discharge, in comparison
to pre-delirium cognitive function, measured by the
CAMCOG. All participants, with and without delirium,
recruited in hospital will be invited for follow up
12 months after their most recent hospital discharge. Fol-
low up will consist of a home visit to complete the Geriat-
ric Mental State-Automated Geriatric Examination for
Computer Assisted Taxonomy (GMS-AGECAT) which
provides a quantitative measure of cognition along with
dementia status and was used in CFAS II. Other relevant
data will also be recorded such as place of residence and
an assessment of physical function.
A control group of non-hospital attendees without evi-
dence of delirium will be sampled on a 2:1 basis,
matched for age, sex and education. Absence of a history
of delirium will be ascertained via clinical notes review
and telephone interview based on the Informant Assess-
ment of Geriatric Delirium Scale (I-AGeD) [34].
Consent
Potential participants will be approached as soon as pos-
sible on admission to hospital. This will not interfere
with clinical care. They will be approached by the chief
Table 1 Standardised diagnostic algorithm for DSM-5 delirium
DSM-5 criteria Test to be performed or information needed
A. Disturbance in attention (i.e., reduced ability to direct,
focus, sustain, and shift attention) and awareness (reduced
orientation to the environment).
Observations by the examiner during the interview
(initiated by questioning such as “can you tell me
what has been going on today?”)
Level of arousal measured using m-RASS and OSLA
Months of the year backwards
Digit span from MDAS
B. The disturbance develops over a short period of time
(usually hours to a few days), represents a change from
baseline attention and awareness, and tends to fluctuate
in severity during the course of a day.
Acute onset and/or fluctuation obtained from
informant history from nursing staff, next of kin
and clinical notes
C. An additional disturbance in cognition
(e.g., memory deficit, disorientation, language, visuospatial
ability, or perception).
Impairment in any of the following domains:
SHORT-TERM MEMORY: three item recall at three
minutes
LONG-TERM MEMORY: when did World War II end?
ORIENTATION: 10 orientation questions from MDAS
LANGUAGE: 3 stage command, naming an object
and explain purpose of object along with fluency,
comprehension and content of conversation
VISUOSPATIAL: Will a stone float on water?
PERCEPTUAL DISTURBANCE: evidence of illusions
or hallucinations by collateral or direct observation/
questioning
D. The disturbances in criteria A and C are not explained
by another pre-existing, established, or evolving
neurocognitive disorder and do not occur in the context
of a severely reduced level of arousal, such as coma.
Information from history/chart/clinical examination
E. There is evidence from the history, physical examination,
or laboratory findings that the disturbance is a direct
physiologic consequence of another medical condition,
substance intoxication or withdrawal (i.e., because of a
drug of abuse or to a medication), or exposure to a
toxin or is because of multiple aetiologies.
Information from history/chart/clinical examination
Abbreviations:
m-RASS modified Richmond Agitation and Sedation Scale [37]
OSLA Observational Scale of Level of Arousal [38]
MDAS Memorial Delirium Assessment Scale [23]
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investigator (SR) or the research nurse. Participants will
be given a maximum of 24 hours to decide. However,
given the low risk and largely observational nature of the
study, it is anticipated that participants or their personal
consultees will be willing to consent before this. They
will also previously have received a participant informa-
tion sheet by post and so some participants may already
be aware of the study.
The inclusion of some participants lacking capacity is
inevitable as the study aims to look at the effect of delir-
ium on cognition and both delirium and dementia can
impair a person’s capacity. A formal capacity assessment
based on the Mental Capacity Act will be performed by
a trained member of the research team, mainly the chief
investigator (SR). Participants will be asked to give con-
sent appropriate to their level of understanding, ranging
from written informed consent to account being taken
of verbal and non-verbal communication in determining
willingness to participate. In those individuals found to
be without capacity to give full written informed con-
sent, a personal consultee will be identified and their ad-
vice sought regarding participation as per Section 32 of
the Mental Capacity Act [35]. As per this guidance, the
personal consultee cannot be a paid carer.
The advantage of re-evaluating CFAS II participants,
as opposed to other study populations, is that they have
already expressed an interest in research by virtue of
their willingness to participate in CFAS II. This may
make conversations with the personal consultee easier as
they will be familiar with research and should be aware
of the wishes and feelings of the participant about taking
part in research studies.
Verbal reconfirmation of the study participant’s willing-
ness to continue with the study will be sought at each
point of contact. Participants who are very distressed or
refuse to engage (whether due to delirium or having the
capacity to refuse assessment on that occasion) will not be
assessed by the research team on that occasion but a rec-
ord of the outcome of the interaction will be documented.
Due to the fluctuating nature of delirium, further contact
will be attempted later. Any patient appearing consistently
distressed by participation or withdrawing consent whilst
having capacity will be excluded from the study without
prejudice to clinical care. As such, every effort will be
made to respect the wishes of the person, both previously
made and at the time the research is undertaken.
If they recover capacity, participants admitted to the
study via a personal consultee will be given the opportunity
to consider whether they would like to continue to be part
of the study and if so, written consent will be obtained.
Data handling and confidentiality
Data will be handled, computerised and stored in ac-
cordance with the Data Protection Act 1998. No
participant identifiable data will leave the study site. Par-
ticipants will be allocated a unique study identifier which
will be used on all data stored in order to ensure ano-
nymity. Caldicott approval has been granted. Personal
data will be regarded as strictly confidential. All study
records, including the consent forms, and investigator
site files will be kept in a locked filing cabinet with re-
stricted access.
Power calculations
We aim to detect a clinically and statistically significant
difference in the annual decrease in the total CAMCOG
(total score 107), between 6 points in delirium participants
and 3 points in participants without delirium. Assuming
that 10% of the cohort (the most conservative end of the
range) is a delirium case and that the standard deviation
of the decrease in CAMCOG is 2.7 points [36], then in
order to detect the desired difference (2-fold) in the
CAMCOG with 90% power, using a two-sided test at the
5% level, 10 participants with delirium at the time of ad-
mission to hospital and 90 participants without delirium
would be needed, i.e. a total of 100 participants. The ana-
lysis would additionally allow for other factors using a re-
gression approach, rather than simply comparing how the
change in CAMCOG from admission to follow-up differs
between the two groups. Also, whilst the calculation
assumes complete data have been collected for all partici-
pants, the analysis will explore the possibility of in-
corporating participants with missing data. The above
calculations are based on a very conservative prevalence
of delirium of 10%. If, for example, the prevalence were
20%, then a total of 55 participants (11 with delirium, 44
without) would be required, based on the assumptions
outlined above.
By applying the expected number of admissions per
age group, based on best available data, to the number
of people within these age groups remaining in the
CFAS II-Newcastle cohort, it is possible to estimate that
450 people will be admitted during the year.
Statistical analysis
The CAMCOG will be used as the primary measure of
global cognitive status when examining the effect on
cognition of an episode of delirium. The distribution of
the values will be considered during the analysis process.
The effect of an episode of delirium on cognition will be
evaluated by comparing CAMCOG score at baseline and
at one year after admission to hospital. Regression ana-
lyses will be used to evaluate the change in cognition in
delirious and non-delirious participants whilst account-
ing for relevant confounders such as age, education and
illness severity.
Drop-out due to mortality is anticipated in both groups
due to the age of participants and the high mortality rates
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associated with both severe illness and delirium. This will
be explored as part of the analysis. The sensitivity of our
results to patterns of missing data and methods for ac-
counting for this will be explored. There is likely to be
some survivor effect and this will be considered. Longitu-
dinally, the labelling of “delirium” and “control” becomes
blurred due to the fluctuating nature of delirium. The pos-
sibility of analysing delirium as a time-varying exposure
will be explored as part of the data analysis. The overall
approach is novel because no previous delirium ascertain-
ment studies have been nested within an existing, well-
characterised cohort allowing baseline characteristics to
be controlled for in the final analysis. Assistance with data
analysis will be sought from collaborators who have ex-
perience in this field and have also previously worked with
the CFAS-II cohort.
The predictive value, in terms of cognitive outcomes,
of the various markers recorded during the acute epi-
sode will be evaluated using multiple regression analysis.
This might include the contributory and/or independent
effects of delirium severity, duration, aetiology or base-
line cognitive function on cognitive outcome.
Discussion
Delirium is common and associated with poor outcomes,
but existing studies are limited by a lack of generalisability
and the use of retrospective delirium ascertainment. The
novel design of this population-based study includes both
baseline cognitive assessments and prospective delirium
evaluation in order to assess robustly the likelihood of the
relationship between delirium and cognitive decline being
independent of any potentially confounding factors. This
study will elucidate the size of the effect of delirium upon
cognitive decline/dementia and may lead on to dementia
prevention trials that focus on delirium intervention.
Given the current lack of both modifiable risk factors and
treatments for dementia, this would be a considerable ad-
vance. Validated methods of delirium prevention do exist
but have not been widely implemented. This study will
add to our understanding of the long-term importance of
delirium prevention.
The prospective nature of the delirium assessments,
and the data to be collected, will increase our under-
standing of the natural history of delirium. As such, this
study could address many unanswered questions of clin-
ical significance in delirium and dementia including the
natural history of delirium, expected outcomes, and the
prognostic value of parameters such as aetiology, dur-
ation, severity or underlying frailty. This would facilitate
accurate and realistic conversations with families and
will have important implications for healthcare planning
and public health initiatives.
Patients and the public have been involved throughout
the development of this study. Patient groups via the
Dementias and Neurodegenerative Diseases Research
Network (DeNDRoN) were consulted regarding study
design, particularly in terms of acceptability. They also
reviewed the lay summary. The proposal was also
reviewed by lay members of the Cognitive Function and
Ageing Study (CFAS) Management Committee. They
supported the application and agreed that the combin-
ation of the two studies will be reciprocally beneficial
with DECIDE enriching CFAS data and vice versa. As
the study progresses, regular meetings with the Alzhei-
mer’s Society monitors will be used to provide updates
on progress and to disseminate findings. There will also
be an open Patient and Public Involvement dissemin-
ation event at the end of the study.
DECIDE will be the first study to prospectively eluci-
date the effect of delirium upon cognitive decline and
dementia independent of baseline cognition and illness
severity and may inform future dementia prevention tri-
als that focus on delirium intervention.
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